NL8702680A - Nieuwe benzogchinolinen en werkwijzen voor het bereiden en toepassen van deze verbindingen. - Google Patents
Nieuwe benzogchinolinen en werkwijzen voor het bereiden en toepassen van deze verbindingen. Download PDFInfo
- Publication number
- NL8702680A NL8702680A NL8702680A NL8702680A NL8702680A NL 8702680 A NL8702680 A NL 8702680A NL 8702680 A NL8702680 A NL 8702680A NL 8702680 A NL8702680 A NL 8702680A NL 8702680 A NL8702680 A NL 8702680A
- Authority
- NL
- Netherlands
- Prior art keywords
- compound
- formula
- free base
- addition salt
- acid addition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 68
- 238000000034 method Methods 0.000 title claims description 16
- 239000002253 acid Substances 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 28
- 239000012458 free base Substances 0.000 claims description 27
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 230000003287 optical effect Effects 0.000 claims description 11
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 102000003946 Prolactin Human genes 0.000 claims description 7
- 108010057464 Prolactin Proteins 0.000 claims description 7
- 239000004202 carbamide Substances 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 229940097325 prolactin Drugs 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- -1 3-dimethylaminopropyl Chemical group 0.000 claims description 5
- 230000028327 secretion Effects 0.000 claims description 5
- 125000004423 acyloxy group Chemical group 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 3
- 230000003291 dopaminomimetic effect Effects 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 2
- 229940005501 dopaminergic agent Drugs 0.000 claims description 2
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 claims 1
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 claims 1
- 150000001491 aromatic compounds Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000005661 deetherification reaction Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 206010017600 Galactorrhoea Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010036832 Prolactinoma Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000010716 Vigna mungo Nutrition 0.000 description 1
- 244000042295 Vigna mungo Species 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000030153 prolactin-producing pituitary gland adenoma Diseases 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000010956 selective crystallization Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/08—Aza-anthracenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3639855 | 1986-11-21 | ||
| DE3639855 | 1986-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8702680A true NL8702680A (nl) | 1988-06-16 |
Family
ID=6314490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8702680A NL8702680A (nl) | 1986-11-21 | 1987-11-10 | Nieuwe benzogchinolinen en werkwijzen voor het bereiden en toepassen van deze verbindingen. |
Country Status (22)
| Country | Link |
|---|---|
| JP (1) | JPS63150264A (enExample) |
| KR (1) | KR880006200A (enExample) |
| AT (1) | AT393836B (enExample) |
| AU (1) | AU604512B2 (enExample) |
| BE (1) | BE1003219A3 (enExample) |
| CH (1) | CH677668A5 (enExample) |
| DK (1) | DK608787A (enExample) |
| ES (1) | ES2011309A6 (enExample) |
| FI (1) | FI875130A7 (enExample) |
| FR (1) | FR2607134A1 (enExample) |
| GB (1) | GB2198129B (enExample) |
| GR (1) | GR871777B (enExample) |
| HU (1) | HUT47914A (enExample) |
| IL (1) | IL84538A (enExample) |
| IT (1) | IT1211920B (enExample) |
| LU (1) | LU87047A1 (enExample) |
| NL (1) | NL8702680A (enExample) |
| NZ (1) | NZ222612A (enExample) |
| PH (1) | PH25125A (enExample) |
| PT (1) | PT86178B (enExample) |
| SE (1) | SE8704551L (enExample) |
| ZA (1) | ZA878717B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3879789A (en) * | 1988-07-22 | 1990-02-19 | Sandoz Ag | Use of benzo(g)quinolines in treatment of nicotine addiction |
| TW357143B (en) * | 1995-07-07 | 1999-05-01 | Novartis Ag | Benzo[g]quinoline derivatives |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526892A (en) * | 1981-03-03 | 1985-07-02 | Farmitalia Carlo Erba, S.P.A. | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas |
| ATE56958T1 (de) * | 1981-10-16 | 1990-10-15 | Sandoz Ag | 1,2,3,4,4a,5,10,10a-octahydrobenzo(g)chinolinderivate mit pharmazeutischer wirkung. |
| GB8602372D0 (en) * | 1986-01-31 | 1986-03-05 | Sandoz Ltd | Organic compounds |
-
1987
- 1987-11-10 NL NL8702680A patent/NL8702680A/nl not_active Application Discontinuation
- 1987-11-12 CH CH4410/87A patent/CH677668A5/de not_active IP Right Cessation
- 1987-11-13 HU HU875063A patent/HUT47914A/hu unknown
- 1987-11-16 BE BE8701295A patent/BE1003219A3/fr not_active IP Right Cessation
- 1987-11-16 FR FR8715917A patent/FR2607134A1/fr not_active Withdrawn
- 1987-11-18 LU LU87047A patent/LU87047A1/fr unknown
- 1987-11-18 IT IT8748620A patent/IT1211920B/it active
- 1987-11-19 DK DK608787A patent/DK608787A/da not_active Application Discontinuation
- 1987-11-19 PT PT86178A patent/PT86178B/pt not_active IP Right Cessation
- 1987-11-19 GB GB8727057A patent/GB2198129B/en not_active Expired - Lifetime
- 1987-11-19 FI FI875130A patent/FI875130A7/fi not_active IP Right Cessation
- 1987-11-19 IL IL84538A patent/IL84538A/xx unknown
- 1987-11-19 NZ NZ222612A patent/NZ222612A/xx unknown
- 1987-11-19 SE SE8704551A patent/SE8704551L/xx not_active Application Discontinuation
- 1987-11-19 AU AU81409/87A patent/AU604512B2/en not_active Ceased
- 1987-11-20 JP JP62294995A patent/JPS63150264A/ja active Pending
- 1987-11-20 AT AT0306187A patent/AT393836B/de not_active IP Right Cessation
- 1987-11-20 ZA ZA878717A patent/ZA878717B/xx unknown
- 1987-11-20 KR KR870013071A patent/KR880006200A/ko not_active Withdrawn
- 1987-11-20 ES ES8703316A patent/ES2011309A6/es not_active Expired - Lifetime
- 1987-11-20 GR GR871777A patent/GR871777B/el unknown
- 1987-11-20 PH PH36098A patent/PH25125A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUT47914A (en) | 1989-04-28 |
| AU8140987A (en) | 1988-05-26 |
| PT86178A (en) | 1987-12-01 |
| BE1003219A3 (fr) | 1992-02-04 |
| CH677668A5 (enExample) | 1991-06-14 |
| SE8704551D0 (sv) | 1987-11-19 |
| FI875130A0 (fi) | 1987-11-19 |
| PH25125A (en) | 1991-02-19 |
| GR871777B (en) | 1988-03-24 |
| NZ222612A (en) | 1991-07-26 |
| FI875130A7 (fi) | 1988-05-22 |
| AU604512B2 (en) | 1990-12-20 |
| GB2198129B (en) | 1990-08-08 |
| ZA878717B (en) | 1989-06-28 |
| FR2607134A1 (fr) | 1988-05-27 |
| GB8727057D0 (en) | 1987-12-23 |
| DK608787A (da) | 1988-05-22 |
| KR880006200A (ko) | 1988-07-22 |
| JPS63150264A (ja) | 1988-06-22 |
| IT8748620A0 (it) | 1987-11-18 |
| IT1211920B (it) | 1989-11-08 |
| LU87047A1 (fr) | 1988-06-13 |
| ATA306187A (de) | 1991-06-15 |
| ES2011309A6 (es) | 1990-01-01 |
| PT86178B (pt) | 1990-11-07 |
| SE8704551L (sv) | 1988-05-22 |
| DK608787D0 (da) | 1987-11-19 |
| AT393836B (de) | 1991-12-27 |
| IL84538A (en) | 1991-12-12 |
| IL84538A0 (en) | 1988-04-29 |
| GB2198129A (en) | 1988-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0077754B1 (en) | Novel pharmaceutically active 1,2,3,4,4a,5,10,10a-octahydrobenzo(g)quinoline derivatives | |
| EP1309594A1 (fr) | Derives de benzimidazole, leur preparation et leur application en therapeutique | |
| Dale et al. | The synthesis and anti‐acetylcholinesterase activities of (+)‐physostigmine and (+)‐physovenine | |
| CS266310B2 (en) | Process for preparing derivatives of benzmide | |
| EP0080115A2 (en) | Hexahydronaphth(1,2-b)-1,4-oxazines, process for their preparation and pharmaceutical formulation containing them | |
| NZ227739A (en) | Substituted 1,4-benzoxazine and benzothiazine derivatives and pharmaceutical compositions; processes for preparation | |
| PT91783B (pt) | Processo para a preparacao de {(diarilmetoxi) alquil}-1-pirrolidinas e piperidinas | |
| US4634708A (en) | Indolophenanthridines useful as dopaminergic and analgesic agents | |
| KR900004145B1 (ko) | 트리사이클릭 화합물의 제조방법 | |
| IL103229A (en) | Imidazolylmethyl-pyridine derivatives their preparation and pharmaceutical compositions containing them | |
| FR2738569A1 (fr) | Nouveaux derives naphtamide de 3 beta-amino azabicyclo octane ou nonane, leur procede de preparation, leur utilisation a titre de medicament antipsychotique | |
| FR2510575A1 (fr) | Nouveaux composes bicycliques, leur procede de preparation et composition pharmaceutique les renfermant | |
| KR20000064811A (ko) | 테트라히드로인돌리진 유도체의 제조법 | |
| FI85702C (fi) | Foerfarande foer framstaellning av tert.-butyl-ergolinderivat. | |
| CS213380B2 (en) | Method of preparation of 2-azaergolines and 2-aza-8/or9/-ergolenes | |
| CA1108156A (en) | Phenanthrene derivatives, their preparation and pharmaceutical compositions containing them | |
| EP0246633B1 (en) | Trans-benzopyran-[4,3-b]-1,4-oxazine derivatives | |
| US3280145A (en) | New indole derivatives and their acid addition salts | |
| CY1399A (en) | 4,5,5a-6-tetrahydrodibenz(cd,f) indoles | |
| AU604512B2 (en) | Octahydrobenzo(g)quinoline-3beta-carbonyl derivatives useful as dopamine receptor stimulating and prolactin secretion inhibiting agents | |
| FR2654340A1 (fr) | Nouveaux derives de benzo [b] phenanthrolines-1,7 leur preparation et leur application en therapeutique. | |
| US3635962A (en) | 4 - bis-morpholino- and 2 | |
| US4602032A (en) | Dibenz[cd,f]indole derivatives, their preparation and pharmaceutical compositions containing them | |
| US3649634A (en) | 4-alkoxy-2 3-dihydro-1h-pyrrolo(2.3-b)quinoline compounds | |
| AU638874B2 (en) | Ergoline derivatives useful as dopamine antagonistic agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BV | The patent application has lapsed |